Nuclera raises €12.0M Series C+ round
13 January 2026· Cambridge, United Kingdom· health, biotechnology, digital_microfluidics, laboratory_automation, software_hardware, b2b
The funding will support further development of eProtein Discovery to enable full-format antibody expression, purification, and binding validation.
Investors
LeadElevage Medical Technologies
Also participating
British Business BankGK Goh
About Nuclera
Stage
Series C+
Headquarters
Cambridge, United Kingdom
Founded
2013
Team Size
51–200
Sectors
healthbiotechnologydigital_microfluidicslaboratory_automationsoftware_hardwareb2b